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Abstract 
 
Objectives: Systemic sclerosis (SSc) is characterized by a progressive microangiopathy that 
contributes significantly to the morbidity of SSc patients. Besides insufficient angiogenesis, 
defective vasculogenesis with altered numbers of endothelial precursor cells (EPCs) might also 
contribute to the vascular pathogenesis of SSc. However, different protocols for isolation, 
enrichment, culture and quantification of EPCs are currently used, which complicate comparison 
and interpretation of the results from different studies.  
Methods: The aim of the EUSTAR expert panel was therefore to provide recommendations for 
standardization of future research on EPCs. Consensus statements and recommendations were 
developed in a face-to face meeting by an expert panel of the basic science working group of 
EUSTAR.  
Results: Cardiovascular risk factors and medications such as statins should be described in detail. A 
detailed description of methods considering isolation, culture, enrichment and detection of EPCs 
should be given. For in vitro culture of EPCs, no protocol has been shown to be superior to another, 
but coating with laminin and type IV collagen would resemble most closely the situation in vivo. 
The endothelial phenotype should be confirmed in all in vitro cultures at the end of the culture 
period. We recommend using CD133, VEGFR2 and CD34 in combination with a viability marker 
for quantification of EPCs in the blood. Finally, exact standard operating procedures for FACS 
analysis are given that should be strictly followed. 
Conclusions: The EUSTAR recommendations will help to unify EPC research and allow better 
comparison between the results of different studies. 
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Introduction 
The first histopathological hallmark of SSc is apoptosis of endothelial cells and subsequent 
vasculopathy. The vasculopathy in SSc patients results in a decreased capillary blood flow, which 
can manifest clinically as finger tip ulcers [1]. Despite the presence of several stimuli that induce 
the formation of new vessels such as tissue hypoxia and increased levels of vascular endothelial 
growth factor (VEGF), appropriate vessel formation does not occur in SSc patients [2, 3].  
New vessels can be formed by angiogenesis and vasculogenesis. Angiogenesis is defined as 
sprouting of fully differentiated endothelial cells from preexisting vessels. In contrast, 
vasculogenesis describes the formation of new vessels de novo by circulating progenitor cells. 
Accumulating evidence suggests that vasculogenesis occurs in the adult and that endothelial 
precursor cells (EPCs) play an important role for the homeostasis of the vascular network. EPCs 
might not only be involved in the formation of new vessels in ischemic tissues, but might also 
contribute to the repair of preexisting vessels [4, 5]. Thus, EPCs might be interesting candidates for 
novel therapeutic approaches. This is indirectly supported by a recent study indicating that stem cell 
transplantation might improve microvascular disease in SSc [6-8]. Furthermore, EPCs could also 
serve as biomarkers for the individual capacity for vascular repair, new vessel formation and 
cardiovascular prognosis [9]. Recent studies suggest that defective vasculogenesis might also 
contribute to the vascular pathogenesis of SSc [1].  
However, different protocols for isolation, enrichment, culture and quantification of EPCs are 
currently used. This complicates the interpretation of the results and might even lead to 
contradictory results. We summarize herein current pitfalls of EPC research and propose 
recommendations for standardization of future research on EPCs. These recommendations are on 
the level of expert opinion and were generated during a face-to face meeting of the basic science 
working group of EUSTAR (EULAR Scleroderma Trials And Research group). The aim of 
EUSTAR is to foster the awareness, understanding and research of scleroderma and its management 
throughout Europe [10]. This includes clinical [11] and basic science [12] research in SSc. The 
following recommendations were also approved by the EULAR Standing Committee for 
International clinical Studies Including therapeutic Trials (ESCISIT). They might not only be of 
interest for EPC research in SSc, but also for other rheumatic diseases such as rheumatoid arthritis 
(RA) and systemic lupus erythematosus (SLE), in which perturbed vasculogenesis has also been 
demonstrated [13-19].  
 
EPCs became important: Summary of current knowledge about EPCs in SSc 
Kuwana et al. first investigated, whether vasculogenesis is impaired in patients with 
systemic sclerosis [20]. In this study, CD34-positive cells were enriched from peripheral-blood 
mononuclear cells by an immunomagnetic technique with a monoclonal antibody to CD34 coupled 
to magnetic beads. EPCs were defined as circulating cells positive for CD34, CD133, and the type 2 
receptor for VEGF (VEGFR2) and quantified by three-colour flow cytometry. Using this definition 
and method of detection, the absolute numbers of EPCs were found to be lower in SSc patients than 
in RA patients and controls. In SSc patients, the EPC count did not correlate with the disease 
subset, disease duration nor the modified Rodnan Skin Score. However, the numbers of EPCs were 
significantly lower in SSc patients with pitting scars. Active fingertip ulcers were observed 
exclusively in patients with the lowest numbers of EPCs. More than 80 % of the adherent, CD133 
and VEGFR2 positive cells expressed also the endothelial cell markers CD31 and the angiopoietin 
receptor Tie-2 and took up acetylated LDL. In contrast, the expression of markers for mature 
endothelial cells such as vascular-endothelium cadherin (VE-cadherin), CD146 and, von Willebrand 
factor was faint or lacking. In a follow-up study using the same techniques, the authors showed an 
increase of circulating EPCs by atorvastatin treatment in patients with SSc. However, the impaired 
functional capacity of EPCs in SSc patients was not improved by atorvastatin [21].  
 Del Papa et al. identified EPCs in whole blood by expression of CD34, VEGFR2 and 
CD133 with FACS [22]. Despite using the same surface markers (with, however, antibodies from a 
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different manufacturer), the results were different and EPCs numbers were found significantly 
increased. Further subgroup analysis showed a negative correlation between the number of EPCs 
and disease duration. Apart from disease duration, no significant correlations were observed 
between EPC count and clinical parameters, in particular with digital ulcers. In addition to 
circulating EPCs, Del Papa et al determined also the number of EPCs in the bone marrow. The 
numbers of cells positive for CD133 was significantly decreased in SSc. To evaluate the ability of 
bone marrow cells enriched for CD133 positive cells to differentiate into endothelial cells, cells 
were cultured in M199 medium supplemented with 10% FBS, VEGF, basic fibroblast growth factor 
(bFGF), and insulin-like growth factor 1 (IGF-1) on fibronectin coated flasks. In a second step, cells 
were purified using fluorescein isothiocyanate (FITC)-labelled agglutinin-1 and anti-FITC coated 
magnetic beads. After 21 days of cultures, colonies obtained from SSc were rare and smaller than 
colonies obtained from healthy individuals and showed signs of senescence and stress.  
 Allanore et al investigated EPC counts in whole blood and potential correlations with 
clinical parameters in patients with SSc, OA and active RA [23]. The authors measured the numbers 
of cells positive for CD34 and CD133 cells, but did not analyze the expression of VEGFR2. The 
numbers of CD34/CD133 double positive cells were significantly higher in SSc than in patients 
with OA, but lower than in RA patients. The numbers of CD34/CD133 double positive cells 
increased in parallel with the European disease activity score. In agreement with Del Papa’s results, 
numbers of CD34/CD133 double cells tended to be higher in early stages of SSc. In another study, 
this group used a method to enrich immature mononuclear cells: Negative lineage (Lin-) 
mononuclear cells were obtained by enrichment using a human progenitor cell enrichment cocktail. 
After incubation with a FcR blocking reagent, these cells were then subjected to triple labelling with 
anti-CD133, anti-CD34 and anti-VEGFR-2. Furthermore, 7AAD was used for viability staining. 
EPCs, defined as Lin-/7AAD-/CD34+/CD133+/VEGFR-2+ cells, were quantified in by cell 
sorting/flow cytometry and by counting late outgrowth colony-forming units (CFU). SSc patients 
displayed higher circulating EPC counts than controls. Lower EPC counts were associated with 
higher Medsger's severity scores and with digital ulcers. The number of colonies correlated with 
levels of EPCs validating the combination of FACS surface markers [24]. 
 
Different subpopulations of EPCs 
Two main populations of EPCs with different origin, function and morphological 
characterisation have been identified, namely a CD14-positive and a CD14-negative subset. Short 
term cultures contain mainly CD14-positive cells. This subset of EPCs consists of 
transdifferentiated monocytes, which are capable of developing into an endothelial phenotype in 
certain culture conditions [25]. In contrast, long-term cultures consist of CD14-negative EPCs, 
which form late outgrowth cultures. The CD14-negative subset of EPCs is often referred to as 
“angioblast-like EPCs” and possesses a high proliferation capacity [26]. Both CD14-positive and 
CD14-negative EPCs can form capillary like structures in vitro. Furthermore, both subsets can 
mediate re-endothelialization after vessel injury, improve neovascularization and can be 
incorporated into vessels after short term-culture under conditions promoting their differentiation 
into EPCs [4].  
 
In vitro culture of EPC  
Current methods of detection and quantification of EPCs by flow-cytometry rely on the 
surface expression of CD34, CD133 and VEGFR2. When assessed by this method, the frequency of 
EPCs in the blood appears considerably low (0.01% - 0.0001% of PBMCs). The low yield obtained 
by the method is a major limitation for functional studies. To increase the yield of putative EPCs, in 
vitro outgrowth techniques are widely used. However, the protocols for culture vary remarkably 
(Figure 1). The vast majority of studies used one of the following three culture media: Medium 199 
(Gibco) has been used for the CFU assay by Hill and co-workers without supplements besides fetal 
bovine serum [9]. In contrast, Shintani et al. added an undefined “endothelial cell growth 
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supplement” [27]. Several other studies used the so-called endothelial growth medium (EGM; 
Clonetics) supplemented with bovine brain extract and human epidermal growth factor. Most 
recently, EGM-2 (Clonetics) has been introduced as an advanced endothelial culture medium 
system. In contrast to EGM, EGM-2 contains well defined concentrations of VEGF-A, human 
fibroblast growth factor-2, human epidermal growth factor, insulin-like growth factor-1, ascorbic 
acid, heparin and hydrocortisone.  
Apart from different culture media, different extracellular matrix proteins have been used for 
the coating of cell-culture dishes, which might also influence the outcome. Some studies have been 
performed on cells expanded on culture dishes coated with collagen, whereas others used 
fibronectin or gelatine coated dishes. 
The different culture protocols might enrich for different cell populations leading to analysis 
of different cells. In the first protocol summarized in Figure 1, all cell populations of the PBMC 
fraction are cultured together. This implies the risk of contamination with mature circulating 
endothelial and monocytic cells. To minimize contamination, some authors included a pre-plating 
step. The rationale behind this pre-plating step is that mature endothelial cells should adhere to the 
culture surface, whereas EPCs should remain in suspension. In this protocol, non-adherent cells are 
removed after 24 to 48 hours of culture and re-plated on coated culture dishes. The re-plated cells 
are kept in culture for various time periods before analysis.  
Besides contamination, another limitation of outgrowth techniques has recently been 
demonstrated. George et al. showed that the frequency of EPCs quantified by this culture method 
does not correlate with the number of CD34/CD133/VEGFR2 positive cells determined by flow-
cytometry [28].  
 
 
Enrichment techniques before FACS  
Immunomagnetic enrichment of cells positive for CD34 and CD133  
CD34 or CD133-positive cells may be enriched from peripheral-blood mononuclear cells by 
immunomagnetic techniques with monoclonal antibodies to CD34 or CD133 coupled to magnetic 
beads. These magnetically labelled cells are then retained on a column placed in a separator, while 
unlabeled cells pass through. The retained cells are then eluted after removal from the magnet. 
 
Enrichment of lineage negative cells 
Lineage negative cells can be enriched from peripheral blood after the depletion of mature 
haematopoietic cells (positive lineage cells). For depletion, lineage positive mononuclear cells may 
be magnetically labelled by using a cocktail of biotin-conjugated antibodies against a panel of so-
called “lineage” antigens (CD2, CD3, CD11b, CD14, CD15, CD16, CD19, CD56, CD123, and 
CD235a). Lineage negative cells may also be obtained by enrichment from whole blood using a 
human progenitor cell enrichment cocktail. This antibody cocktail crosslinks unwanted lineage 
positive cells to red blood cells to form immunorosettes. This increases the density of the unwanted 
(rosetted) cells, such that they pellet along with the free red blood cells when centrifuged over the 
buoyant density medium [24]. 
 
FACS markers for EPCs 
Attempts to enumerate EPCs centred on the use of antibodies to VEGFR2 (KDR) in 
combination with CD34 to identify EPCs. Because neither is specific for EPCs alone or together, it 
is unclear whether the data accurately reflect the number of true EPCs in the circulation. The advent 
of CD133 for use in flow cytometry provided a means for detecting primitive stem cells in the 
circulation. Gehling et al. demonstrated that purified CD133 positive stem cells have the capacity to 
differentiate into endothelial cells [29]. More recent studies have demonstrated that cells positive 
for CD133 and VEGFR2 in the circulation have functional properties of EPCs [30, 31]. Expression 
of CD45, which is a marker of differentiated haematopoietic cells, on these cells has been reported 
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by various groups to be positive or negative [31, 32]. Dim expression of CD45 by these cells might 
be the cause of this confusion; hence, the use of CD45 as a gating reagent for EPCs is not 
supported.  
The phenotyping of EPCs requires a multicolour approach. The use of antibodies to CD133 
and VEGFR2 is highly recommended to increase the specificity of the analysis. CD34 should also 
be added to the former combination although in some instances its lack of specificity might be 
confusing (Table 1). 
 
 Definition “early” 
EPCs 
“late” 
EPCs 
Endothelial 
cells 
Haematopoietic 
stem cells 
CD45 - type I transmembrane protein  
- expressed on all differentiated 
haematopoietic cells except 
erythrocytes  
- assists in cellular activation  
- activates Lck (in T cells) or Syk (in B 
cells)  
 
+ 
 
- 
 
- 
 
+ 
CD14 - membrane-associated 
glycosylphosphatidylinositol-linked 
protein 
- expressed especially macrophages  
- co-receptor for the detection of 
bacterial lipopolysaccharide 
- soluble form sCD14 is secreted by the 
liver and by monocytes 
 
 
+ 
 
 
- 
 
 
- 
 
 
- 
CD34 - monomeric cell surface glycoprotein 
- cell-cell and cell-matrix adhesion 
factor  
- found in the umbilical cord and bone 
marrow as haematopoietic cells and in 
vascular endothelium 
 
+(low)/-
 
+ 
 
+/- 
 
+ 
CD133 - 5-transmembrane protein 
- expressed by a subset of 
haematopoietic stem cells  
- specifically localizes to cellular 
protrusions 
 
- 
 
+ 
 
- 
 
+ 
VEGF
R2  
- 7-transmembrane domain receptor  
- promotes the mitogenic and angiogenic 
activity of VEGF 
+/- + + - 
CD144 - also called VE-cadherin 
- adhesion molecule 
- + + - 
CD146 - cell adhesion molecule of the 
immunoglobulin superfamily  
- expressed in endothelial cells  
- involved in intercellular junctions 
 
- 
 
+ 
 
+ 
 
- 
Table 1: Definition of FACS-surface markers 
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Issues of quality controls for FACS  
Various recommendations for the detection of EPCs by flow cytometry can be made. The 
recommendations include: 
1. The rigorous cleaning of the flow cytometer to avoid contamination of the sample by debris 
or residual cells from a previous analysis  
2. The setting and monitoring of fluorescence detectors sensitivity. 
3. The mandatory collection of a large number of events (at least 500000) to identify an 
adequate number of this scarce population.  
4. The use of a real-time viability stain such as 7-AAD or propidium iodide. Identification and 
exclusion of dead cells, which are a major source of non-specific staining, improve the 
resolution of the assay (Figure 3).  
5. The use of a blocking serum to decrease non-specific binding via Fc receptors, another 
source of non-specific staining. 
6. The establishment of a dump channel to exclude cells not of interest from analysis, which is 
extremely useful.  
 
EUSTAR recommendations for studies of EPCs in SSc  
Accumulating evidence suggests that vasculogenesis occurs in the adult and might play a role for 
vascular homeostasis. However, in SSc, several issues remain unclear and should be in the focus of 
further research: (i) EPCs have only been demonstrated in vascular lesions in animal models of 
ischemia, but not in SSc; (ii) The mechanisms by which EPCs contribute to vascular repair and 
neovascularisation have not fully been elucidated. It remains to be determined, whether EPCs 
mediate their effects in humans independently from mature endothelial cells or whether EPCs 
function more as bystanders of angiogenesis; (iii) Results addressing the numbers of EPCs in the 
blood of SSc are controversial. The initial study suggested a profound decrease of circulating EPCs, 
whereas subsequent studies found increased numbers of EPCs in SSc patients. These results might 
be explained by different disease durations in the patient populations and by different techniques for 
enrichment of cells before FACS analysis. Other important confounding factor might be differences 
in the prevalence of co-existing cardiovascular risk factors. Several medications, in particular 
statins, also affect the numbers of EPCs. Thus, cardiovascular risk factors and medications should 
be given in detail in future studies on EPCs in SSc patients. Considering the heterogeneity of the 
disease and the large number of confounding factors influencing the number of EPCs, studies with 
small number of patients are of limited help and should be avoided in future studies.  
Methodical differences likely also account for different results in EPC studies. Different surface 
markers, enrichment techniques and operating procedures for FACS analysis, and specific culture 
conditions result in the characterization of different subpopulations of EPCs. While we are aware 
that these different subpopulations of EPCs represent different aspects of EPC biology and that 
there is no clear-cut “wrong” or “correct” way of identifying “true” EPCs, this expert panel believes 
that some basic methodical guidelines should be followed in future EPC studies.  
Papers should include a detailed description of methods considering the critical points mentioned 
above. For in vitro culture of EPCs, no protocol has been shown to be superior to another. However, 
as the contents of EGM-2 are best defined, we suggest using this medium for future experiments. 
Systematic studies on the different extracellular matrix components for coating of the culture dishes 
are not available, but we feel that coating with laminin and type IV collagen would be least artificial 
as they resemble most closely the vascular basal membrane. For all in vitro cultures, the endothelial 
phenotype should be confirmed at the end of the culture period. Regarding surface markers, we 
recommend evaluation of CD133, VEGFR2 and CD34 in combination with a viability marker in a 
multiparameter flow cytometer. Finally, standard operating procedures for FACS analysis as 
outlined above should be strictly followed. Our key recommendations are summarized in Table 2.  
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Key recommendations for research on EPCs 
General issues  Detailed described of the methods and materials used 
 Detailed summary of cardiovascular risk factors and medications 
FACS issues  Determination of CD133, VEGFR2 and CD34 in combination with 
a viability marker in a multiparameter flow cytometer 
 Collection of a large number of events 
 Blockade of Fc receptors 
 Experienced investigator 
Culture issues  Use of EGM-2 medium 
 Coating with laminin and type IV collagen 
 Confirmation of the phenotype at the end of the culture period 
Table 2. Key recommendations for research on EPCs 
These recommendations will help to unify future EPC research in the field of SSc and also might 
also be of interest for other rheumatic diseases with abnormal vasculogenesis such as RA and SLE. 
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Figure legends 
 
Figure 1: Overview about the different protocols used for in vitro expansion of angiogenic, EPC-
like cells from peripheral blood mononuclear cells.  
 
Figures 2: Figure 2 a: FACS analysis without the use of a viability marker: the first region (R1) 
sorts the immature mononuclear cells, the second (R2) identifies CD34 positive cells. The third dot 
blot gates R1 and R2, identifying the cells positive for CD34, CD133 and VEGFR2 (EPCs). Figure 
2b: Same sample, with the use of a viability marker (7AAD): a new region is selected (R3), sorting 
only the 7AAD negative cells (exclusion of dead cells). The last dot blot gating R1, R2, and R3 
shows a decreased EPC number compared to the previous analysis. This accounts for a non-specific 
staining of dead cells in the assay performed without 7AAD. 
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